News | November 18, 2014

ASTRO Commends Medicare’s Decision to Cover Annual, Low-Dose CT Screenings

Screenings will benefit patients who have the highest risk of developing lung cancer

Lung cancer, ASTRO, CT Screen, National Lung Screening Trial

Image Courtesy of GE

November 18, 2014 — The American Society for Radiation Oncology (ASTRO) is supporting the Centers for Medicare and Medicaid Services' (CMS) decision to provide coverage for annual lung cancer screening via a low-dose CT screening for those at the highest-risk for lung cancer.  

The Proposed Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N) confirms that there is sufficient evidence to warrant annual lung cancer screening for patients most at risk for developing lung cancer.

The patient criteria for eligibility is as follows: aged 55 to 74; asymptomatic (no signs or symptoms of lung disease); a smoking history of at least 30 pack-years (one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes); or a current smoker or someone who has quit smoking within the last 15 years.

Bruce G. Haffty, M.D., ASTRO chair, FASTRO remarks that lung cancer is the leading cause of cancer death for both men and women in the United States, with more than 160,000 people each year dying from the disease. This surpasses the number of deaths from breast, colon and prostate cancers combined. “With this annual screening in place, we will be able to diagnose patients earlier when treatment can be most successful, which will save thousands of lives,” Haffty says.

CMS’s decision follows the United States Preventive Task Force’s December 2013 recommendation that LDCT is a Grade B screening.

For more information: www.astro.org

Related Content

New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
FDA Clears Aidoc's AI Solution for Flagging Pulmonary Embolism
Technology | Artificial Intelligence | May 15, 2019
Artificial intelligence (AI) solutions provider Aidoc has been granted U.S. Food and Drug Administration (FDA)...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
FDA Approves Zebra Medical Vision's HealthPNX AI Chest X-ray Triage Product
Technology | Artificial Intelligence | May 13, 2019
Zebra Medical Vision has received U.S. Food and Drug Administration (FDA) 510(k) clearance for HealthPNX, an artificial...
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core

The novel nanoparticle is designed to enhance radiation killing of cancer cells in the radiation resistant low-oxygen tumor core. Credit: Wenpei Fan, LOMIN Laboratory, NIBIB.

News | Radiation Therapy | May 08, 2019
Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...